A drug safety evaluation of dapagliflozin for diabetic nephropathies in patients with cardiovascular risk

Abstract

Introduction: Diabetic nephropathy is a significant concern for patients with cardiovascular disease. Dapagliflozin, an SGLT2 inhibitor, has emerged as a promising therapeutic approach to managing diabetic nephropathy and reducing cardiovascular risk.

Areas covered: This review encompasses the research and literature search methodology, including clinical trials and real-world evidence, assessing the safety profile of Dapagliflozin in patients with diabetic nephropathy and cardiovascular risk.

Expert opinion: Dapagliflozin, an SGLT2 inhibitor, has redefined patient-centric care by simultaneously improving glycemic control, cardiovascular health, and renal outcomes in individuals with type 2 diabetes, cardiovascular disease, and nephropathy.

Keywords: Diabetes; SGLT2 inhibitor; cardiovascular risk; dapagliflozin; nephropathy.